Results 191 to 200 of about 27,201 (202)

Lapatinib-associated toxicity and practical management recommendations.

Oncologist, 2007
Beverly Moy
exaly  

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

Cancer Letters, 2008
Yung-Jue Bang, Seock-Ah Im
exaly  

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

Pharmaceutical Research, 2011
Stephen Castellino, Patricia Steeg, Julie Lockman   +2 more
exaly  

Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors

Annals of Oncology, 2012
P C Mack, R Gandour-Edwards, S Christensen   +2 more
exaly  

Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study

Annals of Oncology, 2015
Olivier Trédan, L Slaets, P Vuylsteke
exaly  

Lapatinib for Advanced or Metastatic Breast Cancer

Oncologist, 2012
Jan H M Schellens, Henk-Jan Guchelaar, Jos Beijnen   +2 more
exaly  

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer

Annals of Oncology, 2011
K L Blackwell, H J Burstein, K L Blackwell   +2 more
exaly  

The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis

European Journal of Cancer, 2017
Michele Ghidini, Fausto Petrelli, Gianluca Tomasello   +2 more
exaly  

Lapatinib/trastuzumab

Reactions Weekly, 2019
openaire   +1 more source

Capecitabine/lapatinib

Reactions Weekly, 2019
openaire   +1 more source